Cargando…

PRR11 in Malignancies: Biological Activities and Targeted Therapies

Proline rich 11 (PRR11), initially renowned for its relevance with cell-cycle progression, is a proline-rich protein coding gene in chromosome 17q22-23. Currently, accumulating studies have demonstrated that PRR11 plays a critical role in cellular proliferation, colony formation, migration, invasion...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Wei, Chen, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775115/
https://www.ncbi.nlm.nih.gov/pubmed/36551227
http://dx.doi.org/10.3390/biom12121800
_version_ 1784855564769034240
author Han, Wei
Chen, Liang
author_facet Han, Wei
Chen, Liang
author_sort Han, Wei
collection PubMed
description Proline rich 11 (PRR11), initially renowned for its relevance with cell-cycle progression, is a proline-rich protein coding gene in chromosome 17q22-23. Currently, accumulating studies have demonstrated that PRR11 plays a critical role in cellular proliferation, colony formation, migration, invasion, cell-cycle progression, apoptosis, autophagy and chemotherapy resistance via multiple signaling pathways and biological molecules in several solid tumors. In particular, PRR11 also serves as a promising prognostic indicator in a limited number of human cancers, gradually manifesting its potential application for targeted therapies. In this review, we summarize functional activities, related signaling pathways and biological molecules of PRR11 in various malignancies and generalize potential application of PRR11 for targeted therapies, thereby contributing to further exploration of PRR11 in cancer treatment.
format Online
Article
Text
id pubmed-9775115
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97751152022-12-23 PRR11 in Malignancies: Biological Activities and Targeted Therapies Han, Wei Chen, Liang Biomolecules Review Proline rich 11 (PRR11), initially renowned for its relevance with cell-cycle progression, is a proline-rich protein coding gene in chromosome 17q22-23. Currently, accumulating studies have demonstrated that PRR11 plays a critical role in cellular proliferation, colony formation, migration, invasion, cell-cycle progression, apoptosis, autophagy and chemotherapy resistance via multiple signaling pathways and biological molecules in several solid tumors. In particular, PRR11 also serves as a promising prognostic indicator in a limited number of human cancers, gradually manifesting its potential application for targeted therapies. In this review, we summarize functional activities, related signaling pathways and biological molecules of PRR11 in various malignancies and generalize potential application of PRR11 for targeted therapies, thereby contributing to further exploration of PRR11 in cancer treatment. MDPI 2022-12-01 /pmc/articles/PMC9775115/ /pubmed/36551227 http://dx.doi.org/10.3390/biom12121800 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Han, Wei
Chen, Liang
PRR11 in Malignancies: Biological Activities and Targeted Therapies
title PRR11 in Malignancies: Biological Activities and Targeted Therapies
title_full PRR11 in Malignancies: Biological Activities and Targeted Therapies
title_fullStr PRR11 in Malignancies: Biological Activities and Targeted Therapies
title_full_unstemmed PRR11 in Malignancies: Biological Activities and Targeted Therapies
title_short PRR11 in Malignancies: Biological Activities and Targeted Therapies
title_sort prr11 in malignancies: biological activities and targeted therapies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775115/
https://www.ncbi.nlm.nih.gov/pubmed/36551227
http://dx.doi.org/10.3390/biom12121800
work_keys_str_mv AT hanwei prr11inmalignanciesbiologicalactivitiesandtargetedtherapies
AT chenliang prr11inmalignanciesbiologicalactivitiesandtargetedtherapies